In the primary half (H1) of 2025, Abbott Laboratories carried out effectively in the US medical system sector, with regular growth in its core product traces. According to main information and analytics firm GlobalData, a few of Abbott’s high-volume product traces declined in common promoting value (ASP) in the primary six months of 2025, when in comparison with reporting from the identical interval final yr. However, Abbott’s prime income product traces maintained constant ASPs throughout 2024 and 2025, which means that the corporate stays well-positioned and proof against financial pressures, together with these associated to evolving tariff insurance policies.
When analysing Abbott’s highest-volume products, some nuances emerge. Products that ranked highest by quantity of gross sales in 2024 skilled modest will increase in ASPs whereas these main by quantity in 2025 confirmed no change or a slight decline in ASPs. This sample might replicate altering buying methods amongst US healthcare amenities, doubtlessly arising because of evolving priorities in public well being and value issues.
According to its current monetary report, Abbott delivered a powerful first half in 2025, with its US medical system gross sales rising by 14.8% in comparison with H1 2024. GlobalData’s newest information signifies continued sturdy efficiency throughout a number of key product traces, together with MitraClip, Ensite X, and Tactiflex. In the US cardiovascular market, Abbott holds roughly 18% market share, in response to GlobalData.
Abbott’s US diagnostics noticed a modest decline in year-over-year gross sales in the second quarter of 2025, particularly in point-of-care and speedy diagnostics. This seems to be linked to diminished demand for Covid-19 testing, which had beforehand seen excessive demand. This shift in demand might be accountable for the modifications in a few of Abbott’s high-volume gross sales.
“Abbott Laboratories shows growth in core products amid market shifts” was initially created and printed by Medical Device Network, a GlobalData owned model.
The data on this web site has been included in good religion for common informational functions solely. It will not be supposed to quantity to recommendation on which it is best to rely, and we give no illustration, guarantee or assure, whether or not categorical or implied as to its accuracy or completeness. You should receive skilled or specialist recommendation earlier than taking, or refraining from, any motion on the idea of the content material on our web site.
